Value proposition

DARC, a retinal biomarker with AI, advancing drug development for AMD & glaucoma therapeutics

Novai is a British biotechnology start-up, commercialising DARC Technology, an exploratory retinal biomarker for use in Age-related Macular Degeneration (AMD) & glaucoma clinical studies. DARC combines an innovative patented biologic with a state-of-the-art AI algorithm and uses standard imaging equipment to identify cellular level disease activity.

DARC Technology can be used to measure the impact of current and future therapeutics and interventions by assessment of disease activity whilst identifying non-responders to existing and new interventions, resulting in the avoidance of costly, ineffective or un-required medical management. DARC helps to stratify patients in clinical trials, resulting in the creation of enriched patient cohorts, consisting of those at highest risk of rapid disease progression.

DARC has been developed by Professor M Francesca Cordeiro at University College London through Wellcome Trust funding and is now approved as an exploratory biomarker by the FDA & MHRA.

Following further analysis of Phase II data, several other indications may follow, including Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Diabetes Mellitus and Cancer.

Novai is headquartered in Reading, UK. For more information, please visit our website www.novai.co.uk

Biotechnology, Drug Development, Pharmaceutical, Opthalmology, Artificial Intelligence, Glaucoma, Age-related Macular Degeneration, Retinal, Neurodegeneration, Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Biomarker